113 related articles for article (PubMed ID: 11046074)
21. [Treatment of Alzheimer's disease].
Bombois S; Lebert F; Vellas B; Pasquier F
Rev Prat; 2005 Nov; 55(17):1913-9. PubMed ID: 16396232
[TBL] [Abstract][Full Text] [Related]
22. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
23. Neurodegenerative memory disorders: a potential role of environmental toxins.
Caban-Holt A; Mattingly M; Cooper G; Schmitt FA
Neurol Clin; 2005 May; 23(2):485-521. PubMed ID: 15757794
[TBL] [Abstract][Full Text] [Related]
24. [Usage of drugs with potential adverse effects on cognition in a memory-clinic].
Weih M; Scholz S; Reiss K; Alexopoulos P; Degirmenci U; Richter-Schmidinger T; Kornhuber J
Fortschr Neurol Psychiatr; 2009 Sep; 77(9):523-7. PubMed ID: 19644785
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
Prakash J; Kotwal A; Prabhu H
J ECT; 2006 Sep; 22(3):163-8. PubMed ID: 16957530
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in cholinergic drugs for Alzheimer's disease.
Clader JW
Curr Opin Drug Discov Devel; 1999 Jul; 2(4):311-20. PubMed ID: 19649959
[TBL] [Abstract][Full Text] [Related]
28. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
Studzinski CM; Araujo JA; Milgram NW
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
[TBL] [Abstract][Full Text] [Related]
29. Menopause and disorders of the central nervous system.
Henderson VW
Minerva Ginecol; 2005 Dec; 57(6):579-92. PubMed ID: 16306863
[TBL] [Abstract][Full Text] [Related]
30. The role of semantic knowledge on the cognitive estimation task--evidence from Alzheimer's disease and healthy adult aging.
Della Sala S; MacPherson SE; Phillips LH; Sacco L; Spinnler H
J Neurol; 2004 Feb; 251(2):156-64. PubMed ID: 14991349
[TBL] [Abstract][Full Text] [Related]
31. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
[TBL] [Abstract][Full Text] [Related]
32. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
33. An evaluation of drugs for improving memory in aged monkeys: implications for clinical trials in humans.
Bartus RT; Dean RL; Beer B
Psychopharmacol Bull; 1983; 19(2):168-84. PubMed ID: 6408681
[No Abstract] [Full Text] [Related]
34. [Pharmacology of the memory. Review of cognition activator pharmacology].
Lacomblez L; Bensimon G; Warot D
Rev Prat; 1991 Apr; 41(10):894-6. PubMed ID: 2041992
[TBL] [Abstract][Full Text] [Related]
35. Early human trials in the assessment of cognition activators.
Gamzu ER; Birkhimer LJ; Hoover T; Gracon ST
Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():44-8. PubMed ID: 2186411
[TBL] [Abstract][Full Text] [Related]
36. Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders.
Buccafusco JJ
J Alzheimers Dis; 2008 Dec; 15(4):709-20. PubMed ID: 19096166
[TBL] [Abstract][Full Text] [Related]
37. The families of cognition enhancers.
Fröstl W; Maître L
Pharmacopsychiatry; 1989 Oct; 22 Suppl 2():54-100. PubMed ID: 2690152
[TBL] [Abstract][Full Text] [Related]
38. Memory training programs as a reference to the clinical evaluation of drugs in memory disorders.
Israël L
Arch Gerontol Geriatr Suppl; 1989; 1():223-30. PubMed ID: 2667544
[No Abstract] [Full Text] [Related]
39. Pharmacology of the memory process.
Allain H; Moran P; Bentue-Ferrer D; Martinet JP; Lieury A
Arch Gerontol Geriatr Suppl; 1989; 1():109-20. PubMed ID: 2569314
[TBL] [Abstract][Full Text] [Related]
40. Choosing a target for cognitive enhancers.
Allain H; Bentué-Ferrer D; Decombe R
Clin Ther; 1990; 12(4):298-305; discussion 297. PubMed ID: 2224945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
